Integer Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y

Integer Holdings Corporation (ITGR) reported mixed Q2 2025 results, with revenues of $476.5 million, up 11.4% year-over-year and beating consensus, while adjusted EPS of $1.55, up 19.2% year-over-year, slightly missed estimates. Top-line growth was primarily driven by a robust 24% increase in the Cardio and Vascular segment, benefiting from organic momentum, recent acquisitions, and strong electrophysiology demand, which largely offset a significant decline in the 'Other Markets' segment due to a planned exit. The company also updated its 2025 guidance, projecting full-year revenues of $1.85 billion to $1.876 billion and adjusted EPS of $6.25 to $6.51, indicating continued growth expectations.

Analysis

Integer Holdings Corporation (ITGR) reported mixed second-quarter 2025 results, characterized by a revenue beat and a slight earnings miss. Total revenues grew a robust 11.4% year-over-year to $476.5 million, surpassing consensus estimates by 2.9%, while adjusted EPS of $1.55, though up 19.2% YoY, fell 1.3% short of projections. The company's top-line performance was overwhelmingly driven by its Cardio and Vascular (C&V) segment, which posted 24% reported growth fueled by organic momentum in electrophysiology and contributions from recent acquisitions. This strength effectively masked modest 2.3% growth in the Cardiac Rhythm Management & Neuromodulation (CRM&N) segment and a steep, but strategically planned, 37.9% decline in the Other Markets segment due to the exit from its Portable Medical business. On the profitability front, the margin picture was also bifurcated; gross margin contracted by 30 basis points to 27.1%, but adjusted operating margin expanded by 50 basis points to 17.1%, aided by an 8.8% reduction in R&D spending. The company's updated full-year 2025 guidance projects 8-9% revenue growth and 18-23% adjusted EPS growth, indicating management's confidence that the C&V segment's strength will continue to drive overall corporate performance.

Key Decisions for Investors

• Investors should recognize that the investment thesis for ITGR hinges on the high-growth Cardio & Vascular segment continuing to successfully offset the planned wind-down of the Other Markets segment and modest growth in CRM&N.
• Monitor the company's gross margin closely, as the 30 basis point contraction presents a potential headwind, despite the expansion in operating margin.
• Given that the updated full-year guidance is largely in line with consensus estimates, the current valuation likely reflects the expected growth, suggesting a neutral or 'Hold' stance may be appropriate pending further catalysts.
• It may be prudent to assess ITGR's performance and valuation relative to better-ranked peers mentioned in the report, such as Boston Scientific (BSX), to gauge its competitive positioning within the medical device space.